Health ❯ Healthcare

Drug Efficacy

Weight Loss Drugs Progression-Free Survival Clinical Research Blood Sugar Control Statins Patient Outcomes Clinical Developments Clinical Trials Statistical Significance Therapeutic Potential

Novartis Faces Investor Backlash After Second Late‑Stage Trial Failure

The company is reviewing full del‑desiran data to guide regulator talks with remibrutinib's October readouts serving as the next major test.

Novartis' Pelacarsen Fails Phase 3 After Lowering Lp(a)

MHRA Approves Wegovy Weight‑Loss Tablet as Private Demand Soars

Upstream Bio Sets Phase 3 Start for Verekitug in Severe Asthma and Nasal Polyps

Xenon to Present Topline X-TOLE2 Phase 3 Results in Focal Onset Seizures at 8 A.M. ET Today

Epcoritamab Added to R2 Yields Large Efficacy Gains in Relapsed Follicular Lymphoma

Roivant’s Brepocitinib Succeeds in 52-Week Dermatomyositis Phase 3 as Companies Target 2026 FDA Filing

Regeneron’s Garetosmab Slashes New Bone Lesions in FOP Phase 3, U.S. Filing Planned This Year

Sanofi’s Amlitelimab Meets Phase 3 Goals in Eczema as Shares Fall on Tepid Efficacy

FDA Approves Regeneron and Sanofi’s Dupixent for Bullous Pemphigoid

Statins Linked to 61% Reduced Cancer Mortality in CLL and SLL Patients

Novo Nordisk's Amycretin Shows 22% Weight Loss in Trial, Boosting Stock

New Study Links Ozempic to Increased Risk of Suicidal Thoughts